Combined CB2 receptor agonist and photodynamic therapy synergistically inhibit tumor growth in triple negative breast cancer.

Zhang J, Zhang S, Liu Y, Su M, Ling X, Liu F, Ge Y, Bai M
Photodiagnosis Photodyn Ther. 2018 24: 185-191

PMID: 30240926 · PMCID: PMC6289793 · DOI:10.1016/j.pdpdt.2018.09.006

Triple negative breast cancer (TNBC) is the deadliest form of breast cancer because it is more aggressive, diagnosed at later stage and more likely to develop local and systemic recurrence. Many patients do not experience adequate tumor control after current clinical treatments involving surgical removal, chemotherapy and/or radiotherapy, leading to disease progression and significantly decreased quality of life. Here we report a new combinatory therapy strategy involving cannabinoid-based medicine and photodynamic therapy (PDT) for the treatment of TNBC. This combinatory therapy targets two proteins upregulated in TNBC: the cannabinoid CB2 receptor (CBR, a G-protein coupled receptor) and translocator protein (TSPO, a mitochondria membrane receptor). We found that the combined CBR agonist and TSPO-PDT treatment resulted in synergistic inhibition in TNBC cell and tumor growth. This combinatory therapy approach provides new opportunities to treat TNBC with high efficacy. In addition, this study provides new evidence on the therapeutic potential of CBR agonists for cancer.

Copyright © 2018 Elsevier B.V. All rights reserved.

MeSH Terms (22)

Acetamides Animals Apoptosis Cell Line, Tumor Cell Proliferation Cell Survival Combined Modality Therapy Female Gene Expression Regulation, Neoplastic Humans Indoles Mice Neoplasm Recurrence, Local Phenyl Ethers Photochemotherapy Photosensitizing Agents Quality of Life Receptor, Cannabinoid, CB2 Receptors, GABA Singlet Oxygen Triple Negative Breast Neoplasms Xenograft Model Antitumor Assays

Connections (1)

This publication is referenced by other Labnodes entities: